TG Therapeutics
A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does TG Therapeutics do?
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions.
How much funding has TG Therapeutics raised?
TG Therapeutics has raised a total of $360M in funding. The most recent round on record is Public Stock Offering.
Where is TG Therapeutics headquartered?
TG Therapeutics is headquartered in New York, New York, USA.
When was TG Therapeutics founded?
TG Therapeutics was founded in 2011.
What industry does TG Therapeutics operate in?
TG Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare.
How many employees does TG Therapeutics have?
TG Therapeutics has approximately 497 people on record.